Advertisement
Canada markets closed

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7297
    -0.0001 (-0.01%)
     

  • CRUDE OIL

    82.80
    -0.01 (-0.01%)
     

  • Bitcoin CAD

    87,879.38
    -3,125.01 (-3.43%)
     

  • CMC Crypto 200

    1,387.41
    -36.69 (-2.58%)
     

  • GOLD FUTURES

    2,327.90
    -10.50 (-0.45%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,472.00
    -192.50 (-1.09%)
     

  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • CAD/EUR

    0.6818
    -0.0001 (-0.01%)
     

DNA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of January 18, 2022 in the Class Action Filed on Behalf of Ginkgo Bioworks Holdings, Inc. Limited Shareholders

Newsfile Corp.
·2 min read

New York, New York--(Newsfile Corp. - December 3, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) alleging that the Company violated federal securities laws.

Class Period: May 11, 2021 to October 5, 2021
Lead Plaintiff Deadline: January 18, 2022
No obligation or cost to you.

Learn more about your recoverable losses in DNA:
https://www.kleinstocklaw.com/pslra-1/ginkgo-bioworks-holdings-inc-loss-submission-form?id=21879&from=5

Ginkgo Bioworks Holdings, Inc. NEWS - DNA NEWS

CLASS ACTION CASE DETAILS: The filed complaint alleges that Ginkgo Bioworks Holdings, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's failure to derive real revenue from third-party customers left it almost completely dependent on related parties; (2) as a result, most, if not all, of the Company's revenue came from related parties the Company created, funded, or controlled through its ownership and board seats; (3) the Company was misclassifying and underreporting related party revenue in order to conceal the Company's near total-dependence on related parties; (4) many of the Company's new R&D partners are undisclosed related parties and/or facades; (5) as a result, the Company's valuation was significant less than Defendants disclosed to investors; and (6) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.

ADVERTISEMENT

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Ginkgo Bioworks you have until January 18, 2022 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased Ginkgo Bioworks securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the DNA lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link.

ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/106461